NHS Long Term Plan 2020 - Partner Profile - Fotofinder Systems
Updated: Aug 3
Who are Fotofinder Systems?
The family-run company based in Bavaria, Germany, has been developing medical imaging systems since 1991. FotoFinder is the pioneer and leading manufacturer of imaging system for complete skin cancer detection by means of Automated Total Body Mapping (ATBM) and digital dermoscopy. FotoFinder is a multifunctional platform for mole assessment, hair diagnostics, aesthetics, psoriasis and capillaroscopy all in one device. Our corporate mission is to visualize skin and make standardized photography in medical practice easy and intuitive. This is done by intelligently combining state-of-the-art technology with software, hardware, and camera technology.
How has Fotofinder Systems improved outcomes for the NHS and patients?
FotoFinder has been providing its services to NHS since 2013 and it has improved early skin cancer detection and long-term patient survival in both NHS and many private practices worldwide.
But more importantly, we have also implemented AI (95% sensitivity and 87.5% specificity) and fully integrated Moleanalyzer pro service in the field of skin cancer diagnosis. The AI score is a perfect tool to support doctors in the risk assessment of melanocytic and non-melanocytic skin lesions. This new technology has improved diagnostic accuracy and appropriate treatments, confidence in diagnosis (reduce number of unnecessary primary referrals), patient care management and patient satisfaction by providing a simple and effective long-term patient management and an improved patient flow.
What has been your greatest achievement to date? And were there any measurable outcomes that accompanied this achievement?
FotoFinder is the world’s leading digital dermoscopy system and is the best Total Body Dermoscopy solution with highest quality and reliability for almost 30 years. Our Automated Total Body Mapping (ATBM), substantially has reduced examination time in high-risk patient and helping doctors to document skin and moles over time with brilliant images which can often prove lifesaving. Total body mapping in combination with dermoscopy has proven to be the best method for monitoring high risk patients: e.g. with genetic predisposition like dysplastic nevus syndrome, transplant patients, patients with diagnosed skin cancer or tumour etc. Since, 70% of melanoma develop “de novo” and not from a pre-existing mole, the total body mapping with Bodyscan analysis is the best method for a comprehensive monitoring patient at high risk of developing skin cancer.
ATBM is the choice of Key Opinion Leaders (KOLs) in more than 100 countries, and we are very proud to be a part of their day-to-day practice and research as well as many publications in BJD, EJC, JEADV, IJD, on digital dermoscopy follow up of melanocytic skin lesion and clinical diagnosis of melanoma.
What key opinion leaders say about Total Body Dermoscopy?
“I think that the FotoFinder bodystudio ATBM has the potential to change the way we are doing digital monitoring. Usually, we select lesions by hand-held dermatoscopy, and then we take pictures and follow them up. The potential I see with this machine is that I stop taking care of the single mole, but just do total body, and then I do the side-by-side comparison because I don't have to go into too much detail regarding the morphology of a single globule. I need to know if a lesion is changing symmetrically or asymmetrically and that is what I can get from polarized total body photography.”
PROF. GIUSEPPE ARGENZIANO Professor of Dermatology, Second University of Naples | Italy
“Thanks to the precise high-resolution documentation, new so_ ware tools and the capability to future implementation of machine learning tools, the advanced Total Body Mapping technology will dramatically improve digital follow-up in high-risk patients. The workflow improves by reducing time for acquisition of standardized total body maps with high quality images in 2-D. With the new Total Body Mapping solution, we can potentially reduce the number of individual lesions for a dermoscopic monitoring. Our technical team loves the Total Body Mapping system because of its usability and the professional development. Now, it’s our hope that this new technology will facilitate the management of patients with multiple atypical moles worldwide. With the reduced time for acquisition and evaluation, more patients will benefit from digital follow-up. The simplicity of the technique will also facilitate the standardization of the digital follow-up protocols and the documentation of patients. Future clinical trials will help to elucidate the accuracy of high-resolution Total Body Mapping in the earliest detection of melanoma compared to the two-step method of digital follow-up described in 2002.”
DR. JOSEP MALVEHY Dermatologist, Centro de Diagnosis Dermatológica and Hospital Clinic | Barcelona, Spain
How many organisations/clients currently utilise the service/solution across the UK?
More than 100 experts across UK and Ireland use FotoFinder systems for total body mapping and digital dermoscopy and we are very privileged to work with Royal Marsden Hospital (London), Hammersmith Hospital (London), Royal Glamorgan Hospital (Wales), Nuffield Health Oxford, University Hospital Limerick, Highgate private Hospital, Royal South Hants University Hospital (Southampton), HCA clinic (London), Spire Dunedin Hospital, Rivers Hospital, Stroud general Hospital,
Manchester Royal Infirmary, Cheltenham General Hospital, South Infirmary Victoria Hospital, Withington Community Hospital, Circle bath Hospital, Nuffield health Glasgow Hospital, Jersey General Hospital, Leighton Hospital, Solihull Hospital, Spire Cambridge Lea Hospital, Royal United Hospital Bath NHS Foundation, and many more.
Is there anything you would like to make delegates aware of ahead of the NHS Long Term Plan 2020 conference on 30th November?
FotoFinder ATBM is the world benchmark when it comes to the management of high-risk patients for melanoma, allowing you to document and analyse skin and moles super-fast and with high accuracy. Powered by FotoFinder artificial intelligence (AI), the ATBM workflow saves you time and produces brilliant images that help you to find new and changed lesions fast and easily. All ATBM systems intelligently combine Total Body Photography and dermoscopy. That is the FotoFinder standard for double safety in the earliest detection of skin cancer!
What do you feel are the key points delegates need to digest when considering a partnership with Fotofinder Systems?
The goal is not the early detection of skin cancer, but the earliest detection! FotoFinder helps you to document the entire skin and individual moles over time and to detect pathological changes as early as possible. The two-step method of digital follow-up increases the likelihood of long-term patient survival by helping physicians to visualize new and changed skin lesions as early as possible. This will reduce substantial time and cost for NHS by reducing time of examination and number of unnecessary biopsy and excision respectively.
If you would like to learn more about Fotofinder Systems please visit https://www.fotofinder.de/en/